Liver cancer immunotherapy study halted early
NCT ID NCT05027425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two immunotherapy drugs (durvalumab and tremelimumab) in people with liver cancer who were waiting for a liver transplant. The goal was to see if the drugs could safely shrink tumors and control the disease without causing organ rejection. Only 8 people took part before the study was stopped early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Simmons Comprehensive Cancer Center UT Southwestern Medical Center
Dallas, Texas, 75235, United States
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
Washington University School of Medicine
St Louis, Missouri, 63130, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can everyday drugs shield the liver from Cirrhosis's worst threats?